BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/19/2024 10:24:53 AM | Browse: 67 | Download: 211
 |
Received |
|
2024-01-29 15:17 |
|
Peer-Review Started |
|
2024-01-29 15:18 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-02-20 01:38 |
|
Revised |
|
2024-02-21 22:59 |
|
Second Decision |
|
2024-03-20 02:36 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-03-20 06:19 |
|
Articles in Press |
|
2024-03-20 06:19 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-05-30 23:02 |
|
Publish the Manuscript Online |
|
2024-06-19 10:24 |
| ISSN |
2220-315x (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Eribulin in breast cancer: Current insights and therapeutic perspectives
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Oliver Oey, Wynne Wijaya and Andrew Redfern |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wynne Wijaya, MD, Master's Student, Research Assistant, Department of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, United Kingdom. wynne.wijaya@oncology.ox.ac.uk |
| Key Words |
Eribulin; Breast cancer; Metastatic breast cancer; Chemotherapy; Efficacy; Safety |
| Core Tip |
Eribulin is a non-taxane chemotherapeutic agent which is utilised for the treatment of locally advanced or metastatic breast cancer patients who have progressed after 2-3 lines of taxane or anthracycline-based regimen. Eribulin’s non-mitotic properties which include its anti-mesenchymal, immunomodulating and vascular remodelling features could make it a perfect candidate in becoming adjuncts to standard treatment regimen for breast cancer across different subtypes. In the era of targeted therapy, immunotherapy and antibody-drug conjugates, we review current evidence to elucidate whether eribulin still has a role to play in earlier and later-line settings both as a single agent and in combination with other agents in patients with metastatic breast cancer across all subtypes of breast cancer. |
| Publish Date |
2024-06-19 10:24 |
| Citation |
<p>Oey O, Wijaya W, Redfern A. Eribulin in breast cancer: Current insights and therapeutic perspectives. <i>World J Exp Med</i> 2024; 14(2): 92558</p> |
| URL |
https://www.wjgnet.com/2220-315x/full/v14/i2/92558.htm |
| DOI |
https://dx.doi.org/10.5493/wjem.v14.i2.92558 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
